Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

We conducted the Apixaban Cancer Associated Thrombosis ... with active cancer who had completed at least 6 months of anticoagulant therapy for proximal deep-vein thrombosis or pulmonary embolism.

Two Phase III trials found that apixaban was more effective for stroke prevention than either aspirin or warfarin in patients with atrial fibrillation (AF), with a similar (versus aspirin ...

New data from a clinical trial suggest that apixaban, an anticoagulant that’s widely been prescribed to promote recovery in patients with severe cases of COVID-19, doesn’t offer any discernable ...

Perspective from Geoffrey Barnes, MD, MSc CHICAGO — For patients with cancer requiring extended anticoagulant therapy, a strategy of reduced-dose apixaban was noninferior to full-dose apixaban ...

The results come at a bad time for Xarelto, which is playing catch-up with Bristol-Myers Squibb’s rival novel oral anticoagulant, Eliquis. In the last quarter, Eliquis took a commanding lead ...

"The only dose regimen that should be used after this study should be the reduced-dose regimen and this has been demonstrated with apixaban," Mahé said at an ACC press conference. After cancer-related ...

"In these OAC-naive patients, asundexian was associated with a slight increase in stroke rates but demonstrated a lower risk ...

BMS is preparing for the loss of patent protection on some of its top-selling medicines, including cancer immunotherapy Opdivo (nivolumab) and anticoagulant Eliquis (apixaban), adding to the ...